This is a composition patent covering myocardial and fibroblast cell preparations that are useful for administration in the post-infarct myocardium. This approach is interesting and a similar approach seems to have been used clinically by the company Bioheart.
View this patent on the USPTO website.
You must be signed-in to add your comments.
Sign-in now or Join the StemCellPatents.com Community for free.